Product Name: ERK5 (218-224) pY221
Product Number: PE-04AZI00
Size: 200 µg      Price:9.00
1 mg      $US18.00
Peptide Name: ERK5 (218-224) pY221

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y221 phosphorylation stimulates phosphotransferase activity, and regulates apoptosis.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: MTE-pY-VAT

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 892.89 Da

Peptide Purity Percent after Synthesis and Purification: >50

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Scientific Background: ERK5 (MAPK7) is a protein-serine/threonine kinase of the CMGC group and MAPK family. It is important in controlling a cell's proliferation, differentiation, and cell survival. Phosphorylation of T219 and Y221 by MEK5 (MAP2K5) increases the phosphotransferase activity of ERK5. MEK5 is activated in response to hyperosmolarity, hydrogen peroxide, and epidermal growth factor (EGF). ERK5 may be a tumour requiring protein (TRP). Although there has been no direct linkage of ERK5 to formation of carcinomas in humans in vivo, in vitro ERK5 over-expression has been shown to increase metastasis, and ERK5 inhibition has been shown to inhibit osteosarcoma cell motility. Upregulation of the MEK5 gene has been noted in breast, prostate, and liver cancer.